Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer (2024)

Table of Contents
Data availability References Acknowledgements Funding Author information Authors and Affiliations Contributions Corresponding author Ethics declarations Competing interests Ethics approval and consent to participate Consent for publication Additional information Supplementary information Supplementary Tables and Figures Rights and permissions About this article Cite this article References

Data availability

Data are available at request from the corresponding author.

References

  1. Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645–59.

    Article CAS PubMed Google Scholar

  2. Modi S, Saura C, Yamash*ta T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21.

    Article CAS PubMed Google Scholar

  3. Doi T, sh*tara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmaco*kinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512–22.

    Article CAS PubMed Google Scholar

  4. Modi S, Jacot W, Yamash*ta T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387:9–20.

    Article CAS PubMed PubMed Central Google Scholar

  5. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–512.

    Article PubMed PubMed Central Google Scholar

  6. de Nonneville A, Goncalves A, Mamessier E, Bertucci F. Sacituzumab govitecan in triple-negative breast cancer. Ann Transl Med. 2022;10:647.

    Article PubMed PubMed Central Google Scholar

  7. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41.

    Article CAS PubMed Google Scholar

  8. Hurvitz SA, Bardia A, Punie K, Kalinsky K, Cortés J, O’Shaughnessy J, et al. 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: findings from the phase III ASCENT study. Ann Oncol. 2022;33:S200–1.

    Article Google Scholar

  9. Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40:LBA1001.

    Article Google Scholar

  10. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95.

    Article CAS PubMed Google Scholar

  11. Huppert L, Mahtani RL, Fisch SC, Dempsey N, Premji S, Taylor A, et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): updated data and subgroup analyses by age, sites of disease, and use of intervening therapies. J Clin Oncol. 2024;42:1083.

  12. Abelman RO, Spring L, Fell G, Davis A, Hensing W, Ryan P, et al. Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis. Cancer Res. 2024;84:PS08-0.

  13. Raghavendra AS. Antibody-drug conjugates (ADCs) in breast cancer: real world analysis of outcomes. 2023. https://sabcs2023.eventscribe.net/fsPopup.asp?Mode=posterinfo&PosterID=623611.

  14. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology–College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2023;147:993–1000.

    Article CAS PubMed Google Scholar

  15. Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2023;43:297–337.

    Article Google Scholar

  16. Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11:2436–45.

    Article CAS PubMed PubMed Central Google Scholar

  17. Spring L, Tolaney SM, Desai NV, Fell G, Trippa L, Comander AH, et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial. J Clin Oncol. 2022;40:512.

    Article Google Scholar

  18. Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148–56.

    Article CAS PubMed Google Scholar

Download references

Acknowledgements

We thank the biostatistics unit of Oncopole Claudius Regaud for their support and Dr. Gail Taillefer, native English speaker experienced in scientific publication, for her review of the manuscript.

Funding

The authors received no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France

    F. Poumeaud&F. Dalenc

  2. Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France

    M. Morisseau&B. Cabarrou

  3. Department of Medical Oncology, Institut Curie, Paris, France

    L. Cabel&D. Loirat

  4. Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France

    A. Gonçalves&A. de Nonneville

  5. Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 – CNRS 5286), Lyon, France

    C. Rivier&O. Trédan

  6. Department of Medical Oncology, Institut de cancérologie de l’Ouest, Saint-Herblain, France

    E. Volant&J.-S. Frenel

  7. Department of Medical Oncology, Centre Georges-François Leclerc, INSERM U1231, Dijon, France

    S. Ladoire

  8. Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France

    W. Jacot

  9. Department of Medical Oncology and Cellular Therapy, Faculté de médecine Sorbonne Université, Hôpital Tenon, Paris, France

    M. Jamelot

  10. Department of Medical Oncology, Hôpital de la Pitié-Salpêtrière, Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Paris, France

    H. Foka Tichoue

  11. Department of Medical Oncology, Institut de Cancérologie de l’Ouest Pays de la Loire, Angers, France

    A. Patsouris

  12. Department of Medical Oncology, INSERM U976, Université de Paris Cité, Hopital Saint Louis, Paris, France

    L. Teixeira

  13. Department of Medical Oncology, Institut Curie, Saint-Cloud, France

    F.-C. Bidard

  14. Versailles Saint-Quentin University, Paris Saclay, Saint-Cloud, France

    F.-C. Bidard

  15. Clinical Trials Department – Breast Cancers, Institut Bergonié, Bordeaux, France

    M. Brunet

  16. Department of Medical Oncology, Centre François Baclesse, Caen, France

    See Also
    High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy8.3: A Confidence Interval for a Population Standard Deviation Unknown, Small Sample CasePregnancy Ultrasounds Week by Week

    C. Levy

  17. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France

    C. Bailleux

  18. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

    A. Deleuze

  19. Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France

    L. Uwer

  20. Department of Medical Oncology, Centre Hospitalier Universitaire de Limoges, Limoges, France

    E. Deluche

  21. Department of Medical Oncology, Centre Hospitalier de la côte basque, Bayonne, France

    T. Grellety

  22. Department of Pathology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France

    C. Franchet

  23. Department of Medical Oncology, University Hospital, Nimes, France

    F. Fiteni

  24. UMR INSERM IDESP—Desbrest Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France

    F. Fiteni

  25. Department of Medical Oncology, Institut de Cancérologie de Strasbourg Europe, Strasbourg, France

    H. Bischoff

  26. Department of Medical Oncology, Centre Henri Becquerel, Rouen, France

    R. Vion

  27. University Paris-Saclay, Gustave Roussy, INSERM U981, Molecular Predictors and New Targets in Oncology, Villejuif, France

    M. Pagliuca

  28. Division of Breast Medical Oncology, Instituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia

    M. Pagliuca

  29. Departmentof Medical Oncology, Institut Gustave Roussy, Paris, France

    B. Verret

  30. Department of Medical Oncology, Centre Oscar Lambret, Lille, France

    S. Bécourt

  31. Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université Lyon 1, Lyon, France

    T. Reverdy

Authors

  1. F. Poumeaud

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  2. M. Morisseau

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  3. L. Cabel

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  4. A. Gonçalves

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  5. C. Rivier

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  6. O. Trédan

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  7. E. Volant

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  8. J.-S. Frenel

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  9. S. Ladoire

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  10. W. Jacot

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  11. M. Jamelot

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  12. H. Foka Tichoue

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  13. A. Patsouris

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  14. L. Teixeira

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  15. F.-C. Bidard

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  16. D. Loirat

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  17. M. Brunet

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  18. C. Levy

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  19. C. Bailleux

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  20. B. Cabarrou

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  21. A. Deleuze

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  22. L. Uwer

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  23. E. Deluche

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  24. T. Grellety

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  25. C. Franchet

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  26. F. Fiteni

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  27. H. Bischoff

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  28. R. Vion

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  29. M. Pagliuca

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  30. B. Verret

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  31. S. Bécourt

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  32. T. Reverdy

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  33. A. de Nonneville

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  34. F. Dalenc

    View author publications

    You can also search for this author in PubMedGoogle Scholar

Contributions

FP and FD: conceived and designed the study that led to the submission, acquired data, drafted and revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. MM: played an important role in interpreting the results, drafted and revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. BC: played an important role in interpreting the results, revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. JSF, WJ and AdN: played an important role in interpreting the results, acquired data, revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. LC, AG, CR, OT, EV, SL, MJ, HF, AP, LT, F-CB, DL, MB, CL, CB, AD, LU, ED, TG, CF, FF, HB, RV, MP, BV, SB and TR: acquired data, revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study.

Corresponding author

Correspondence to F. Poumeaud.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

All participants agreed to participate in this study. The project complies with the reference methodology MR-004 and has been registered in the public directory of the Health Data Hub (F20230615115722). The methods were performed in accordance with relevant guidelines and regulations and approved by CNIL and the Projects Review and Ethical Committee of the Oncopole Claudius Regaud - IUCT-Oncopole (registration number: 23RDSEIN07).

Consent for publication

No individual personal data is shared.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer (1)

Cite this article

Poumeaud, F., Morisseau, M., Cabel, L. et al. Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer. Br J Cancer (2024). https://doi.org/10.1038/s41416-024-02766-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41416-024-02766-9

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer (2024)

References

Top Articles
Asian Roasted Green Beans Recipe (Paleo, Whole30, Vegan)
Saigon Cinnamon Ginger Cookies
'World's Greatest Pizza' no more? Anthony’s to close last Europe location as AAFES looks to phase out the brand
Anthony's Restaurant - View Menu & Order Online - 258 Main St, Torrington, CT 06790 - Slice
Client Relations Contact | Morgan Stanley
Contact Us | Morgan Stanley
Cream Of Coconut Jewel
Edict Of Force Poe
Newburyport/Rockport Line | Commuter Rail
Beginner's Guide to the Commuter Rail | MBTA User Guides
Hoi4 Garrison Template
Sekiro: Shadows Die Twice Achievement Guide & Road Map
Latest Posts
32 German Dessert Recipes from Oma's Kitchen
Polish Coffee Cake (my grandma's recipe!) - Belle Vie
Article information

Author: Kieth Sipes

Last Updated:

Views: 5893

Rating: 4.7 / 5 (47 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Kieth Sipes

Birthday: 2001-04-14

Address: Suite 492 62479 Champlin Loop, South Catrice, MS 57271

Phone: +9663362133320

Job: District Sales Analyst

Hobby: Digital arts, Dance, Ghost hunting, Worldbuilding, Kayaking, Table tennis, 3D printing

Introduction: My name is Kieth Sipes, I am a zany, rich, courageous, powerful, faithful, jolly, excited person who loves writing and wants to share my knowledge and understanding with you.